These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 10511062)

  • 1. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
    Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
    Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
    Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
    Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
    Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
    Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
    Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
    J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
    Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
    Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
    Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
    Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
    Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
    Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
    Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
    Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
    Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
    Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress of tailor-made treatment of peptic ulcer].
    Aoyama N; Shirasaka D; Okumura K
    Nihon Rinsho; 2002 Jan; 60(1):174-81. PubMed ID: 11808330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
    He N; Huang SL; Zhu RH; Tan ZR; Liu J; Zhu B; Zhou HH
    Xenobiotica; 2003 Feb; 33(2):211-21. PubMed ID: 12623762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.